SC-4289

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
SC-4289
SC-4289.svg
Clinical data
Synonyms6-[1'-Ethyl-2',2'-dimethyl-3'-hydroxy]propyl-β-naphthol-2-benzyl ether[1]
Routes of
administration
By mouth
Drug classNonsteroidal estrogen
Identifiers
Chemical and physical data
FormulaC24H28O2
Molar mass348.486 g·mol−1
3D model (JSmol)

SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed.[2][3]

References[edit]

  1. ^ Berichte über die gesamte Physiologie und experimentelle Pharmakologie. Springer-Verlag. p. 332,378.
  2. ^ a b Robinson, R. W., Cohen, W. D., & Higano, N. (1956, January). Serum lipid and estrogenic effects of two new „weak estrogens“ in male patients with coronary atherosclerosis. In Circulation (Vol. 14, No. 3, pp. 489-490). 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106: LIPPINCOTT WILLIAMS & WILKINS. http://circ.ahajournals.org/content/circulationaha/14/3/local/back-matter.pdf
  3. ^ DAVIS FW, SCARBOROUGH WR, MASON RE, SINGEWALD ML, BAKER BM (1958). "Experimental hormonal therapy of atherosclerosis: preliminary observations on the effects of two new compounds". Am. J. Med. Sci. 235 (1): 50–9. PMID 13487586.